Introduction {#s1}
============

Glycated hemoglobin (HbA~1c~) reflects the level of blood glycemia and is commonly used to monitor glycemic control in diabetes and to diagnose type 2 diabetes. Genome-wide association studies (GWAS) have revealed \>60 genetic variants to be associated with HbA~1c~ in individuals without diabetes ([@B1]--[@B6]). A recent GWAS of multiple ethnic groups confirmed 18 variants previously associated with HbA~1c~ and added 42 new loci ([@B6]). Some of the variants affect biological pathways maintaining glucose homeostasis. For example, single nucleotide polymorphisms (SNPs) in or near glucokinase (*GCK)* and melatonin receptor 1B (*MTNR1B)* are known to be associated with HbA~1c~, fasting plasma glucose, and β-cell function ([@B3]). HbA~1c~ is further influenced by genes and pathways that affect erythrocytes. In particular, SNPs in hemochromatosis (*HFE)* and hexokinase 1 *(HK1*) ([@B3]) have an effect on HbA~1c~ through nonglycemic pathways that affect erythrocyte physiology and survival.

HbA~1c~ reflects the glycemic load over ∼3 months ([@B7]), and traits such as hemoglobinopathies, alterations in intracellular glucose metabolism, or defects of glucose transport into erythrocytes affect HbA~1c~. In addition, diet, drugs, and insulin administration affect HbA~1c~ in individuals with type 1 diabetes (T1D) who have little to no endogenous insulin production and, thus, rely on an external source of insulin to ensure glucose uptake in cells. Despite a strong environmental stimulus, HbA~1c~ levels are correlated between both dizygotic twins and monozygotic twins concordant or discordant for T1D ([@B8]). Heritability estimates for HbA~1c~ in individuals without diabetes range from 27% to 62% ([@B8],[@B9]), thus providing evidence for a genetic component for the trait.

To date, one GWAS on HbA~1c~ has been conducted in individuals with T1D in the Diabetes Control and Complications Trial (DCCT) ([@B10]). The authors found that rs1358030 near sortilin-related VPS10 domain--containing receptor 1 (*SORCS1)* was associated with HbA~1c~ *(P* \< 2.2 × 10^−9^). The current study aims to define more genetic variants associated with HbA~1c~ using GWAS of 4,622 individuals with T1D from the Finnish Diabetic Nephropathy (FinnDiane) Study and attempts to replicate GWAS results in five additional cohorts including, altogether, 3,097 individuals with T1D.

Research Design and Methods {#s2}
===========================

Phenotypes {#s3}
----------

### HbA~1c~ {#s4}

FinnDiane is a nationwide, comprehensive multicenter study launched in 1997. Local ethics committees approved the study protocol, and participants gave informed consent before participation. The study was performed in accordance with the Declaration of Helsinki. HbA~1c~ was measured with standardized laboratory methods locally from a blood sample taken during the visits to the FinnDiane study centers. Additional HbA~1c~ values were collected from laboratory records both before and after the FinnDiane visit. A shift from high-performance liquid chromatography method to immunoassays was seen in many laboratories during the HbA~1c~ collection time (1 January 1991--1 June 2016). In Finland, the HbA~1c~ measurements show a high correlation with the DCCT reference method ([@B11]). HbA~1c~ measurements from \<1 year of diabetes diagnosis and the measurements after end-stage renal disease (ESRD) diagnosis were excluded. A median of 19 HbA~1c~ measurements per person (range 1--129) were collected ([Supplementary Fig. 1](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db18-0573/-/DC1)). Phenotype in the GWAS was an intrapersonal mean HbA~1c~, and it roughly followed normal distribution ([Supplementary Fig. 2](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db18-0573/-/DC1)). In the replication cohorts, a mean of natural log-transformed HbA~1c~ was used. Similar phenotypic values were subsequently calculated in FinnDiane to enable comparison of effect sizes (β) in the meta-analysis.

### Clinical Parameters {#s5}

At the FinnDiane visit, each patient underwent a thorough clinical investigation as previously described ([@B12]). The GWAS covariates age and diabetes duration were calculated at the intrapersonal mean date of HbA~1c~ measurements. Micro- or macroalbuminuria was defined based on the urinary albumin excretion rate (AER) in two out of three consecutive timed overnight or 24-h urine collections as previously described ([@B12]). ESRD was defined as ongoing dialysis or the patient having received a kidney transplant. ESRD diagnosis year was verified from hospital records. Hematological measurements were taken from whole blood samples of 429 individuals using flow cytometry in the Helsinki University Central Hospital Laboratory.

Statistical Methods and Analyses {#s6}
--------------------------------

### Patient Selection {#s7}

Individuals with age at diabetes onset of \<40 years, insulin treatment initiated within 1 year of the diabetes diagnosis, and one or more HbA~1c~ measurements were selected from FinnDiane. Relatedness of individuals was calculated with KING 1.40 ([@B13]). Among first-degree family members, the individual with the least number of HbA~1c~ measurements (*n*HbA~1c~) was excluded, and altogether 4,622 individuals were included in the GWAS.

After also excluding more distantly related individuals according to the estimated genetic relationship matrix (≥0.05), we calculated heritability in 4,319 individuals. Narrow-sense heritability of HbA~1c~ (*h*^2^) was the proportion of the phenotypic variance explained by the additive effects of the genotyped SNPs with or without covariates sex, age, duration, genotyping batch, and *n*HbA~1c~ (GCTA, version 1.24.4) ([@B14]).

### Power Calculations {#s8}

Power calculations were performed with Quanto, version 1.2.4 (<http://biostats.usc.edu/Quanto.html>), using α-level of 5 × 10^−8^ (genome-wide significance). In the GWAS, we had 94% power to detect variants with a minor allele frequency (MAF) ≥5% and an effect size (β) 0.40 (nontransformed HbA~1c~ \[%\] \[[Supplementary Table 1](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db18-0573/-/DC1)\]). In the replication cohort (*n* = 3,097), we had \>57% and 99% power (two-sided α = 0.05, β = 0.30) to replicate variants with MAFs 1--5% or MAFs ≥5%, respectively.

### Genotyping and GWAS {#s9}

SNP genotyping was performed with HumanCoreExome-12 v. 1.0, -12 v. 1.1, or -24 v. 1.0 BeadChip (Illumina, San Diego, CA). SNPs with low genotyping call rate, deviation from Hardy-Weinberg equilibrium, MAF \<1%, Mendelian inconsistency, allele frequency difference \>20% (MAF ≥5%), or allele frequency difference \>5% (MAF \<5%) with 1000 Genomes European (EUR) population were filtered.

After quality control, phased haplotypes (SHAPEIT v2.r837) ([@B15]) of 316,899 SNPs were used for imputation with 1000 Genomes EUR phase 3, version 5 ([@B16]), using Minimac3/Minimac3-omp v1.0.14 ([@B17]). A total of 6,019 individuals passed quality control when samples with genotyping rate \<0.95 or extreme heterozygosity, sample mix-ups, and genetic outliers were removed.

GWAS was performed with dosages of 8,354,674 variants with imputation quality *r*^2^ ≥ 0.7 with PLINK v1.9b3.26 ([@B18]) using linear regression with covariates sex, age, diabetes duration, *n*HbA~1c~, genotyping batch, and 10 first principal components that were calculated with the EIGENSTRAT, version 3.0 ([@B19]). A genomic inflation factor λ was 1.003 ([Supplementary Fig. 3](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db18-0573/-/DC1)).

Altogether, 1,489 and 1,863 individuals were genotyped with the TaqMan technology and ABI Prism 7000/7900HT Sequence Detection Systems and SDS 2.3 software (Life Technologies, Foster City, CA) to verify the imputed genotypes of rs2085277 and rs17076364, respectively. Of the TaqMan-genotyped individuals, 1,259 of 1,489 (84.6%) for rs2085277 and 1,545 of 1,863 (82.9%) for rs17076364 were included in the HbA~1c~ GWAS.

### Longitudinal HbA~1c~ {#s10}

Longitudinal HbA~1c~ data were studied with linear mixed models (nlme package in R, version 3.3.3) in 4,153 individuals with three or more HbA~1c~ measurements. The top SNPs were analyzed with continuous time including diabetes duration (at first HbA~1c~), sex, age, genotyping batch, and 10 first principal components as covariates assuming random intercept and slope. The best model (lowest Akaike information criterion) had an autocorrelation structure of order 1 with continuous time covariate and a combined covariance structure with exponential variances for fitted model values and separate variances for HbA~1c~ measurements from different decades of diabetes duration.

### Phenotypic Comparisons {#s11}

Groups were compared with Student *t* test, Welch *t* test, or Mann-Whitey *U* test in R. Histograms were used for evaluating normality. Linear regression was used to study phenotypic associations with covariates.

### Replication {#s12}

#### T1D Cohorts. {#s13}

Replication of the top SNPs was conducted in DCCT/Epidemiology of Diabetes Interventions and Complications (EDIC), the Wisconsin Epidemiologic Study of Diabetic Retinopathy (WESDR), the Coronary Artery Calcification in Type 1 Diabetes (CACTI) study, the Pittsburgh Epidemiology of Diabetes Complications (EDC) study, and the Renin Angiotensin System Study (RASS) comprising altogether 3,097 individuals with T1D ([Fig. 1](#F1){ref-type="fig"} and [Supplementary Table 2](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db18-0573/-/DC1)). Individuals with conventional (*n* = 667) or intensive (*n* = 637) treatment of diabetes during DCCT were analyzed separately. CACTI was also divided (clinic, *n* = 265, and nonclinic, *n* = 253). SNPs with imputation quality *r*^2^ ≥ 0.6 and MAF ≥1% in the individual replication cohorts were included in the meta-analysis. These SNPs were replicated in one to seven cohorts comprising 253--3,097 individuals. A mean of natural log-transformed HbA~1c~ was the phenotype used in the replication cohorts, and to get comparable effect sizes (β) the association of the top SNPs and similarly transformed HbA~1c~ was calculated in the discovery cohort. Thereafter, a fixed-effects meta-analysis based on βs and SEs was performed with GWAMA ([@B20]).

![Outline of the GWAS for HbA~1c~ in the FinnDiane cohort. 1000G, 1000 Genomes.](db180573f1){#F1}

#### Populations Without Diabetes and Literature Search. {#s14}

The top nine independent variants were compared with publicly available data from GWAS meta-analyses of up to 123,517 individuals without diabetes of European ancestry ([@B6]). For variants not included in the GWAS by Wheeler et al. ([@B6]), we searched for proxy variants (*r*^2^ ≥ 0.3) in the 1000 Genomes EUR population using LDlink ([@B21]) (<https://analysistools.nci.nih.gov/LDlink>). Seven out of nine SNPs or proxy variants had HbA~1c~ association data available. In addition, replication of three genome-wide significant SNPs on chromosome 13 was performed in the GWAS data from individuals with East Asian ancestry (*n* = 23,461), since these SNPs were not available in the Europeans, likely due to their low MAFs. Thereafter, we compared 86 previously reported variants for HbA~1c~ with our GWAS results: 11 variants from the DCCT GWAS ([@B10]) and 75 variants from GWAS of individuals without diabetes.

### Genetic Risk Scores {#s15}

Genome-wide significant autosomal SNPs in the largest HbA~1c~ GWAS ([@B6]), which had MAF ≥1% and *P* \< 0.01 also in the Europeans, were selected for genetic risk score (GRS). GRS-ALL comprised all 55 SNPs, and like Wheeler et al. ([@B6]), we calculated separate GRS for erythrocytic SNPs (*n* = 19) (GRS-E) and glycemic SNPs (*n* = 18) (GRS-G). GRS were the sum of expected number of risk alleles weighted by the effect size (β) of the SNP in the Europeans, multiplied by the number of SNPs and divided by the sum of βs. Association of the GRS with HbA~1c~ was studied using linear regression with covariates age, sex, diabetes duration, and *n*HbA~1c~.

After the FinnDiane GWAS, a weighted GRS, GRS~FD~, was created from nine noncorrelated SNPs showing significant or suggestive association with HbA~1c~ (*P* \< 5 × 10^−6^). GRS~FD~ was tested for associations with diabetes duration, diabetic nephropathy (DN), and laser-treated diabetic retinopathy.

### In Silico Analyses {#s16}

The closest genes were searched (Ensembl transcripts downloaded from [https://genome.ucsc.edu/cgi-bin/hg Tables](https://genome.ucsc.edu/cgi-bin/hgTables) \[July 2017\]) for variants with *P* \< 0.001 in the GWAS. A total of 9,742 SNPs were mapped to 4,470 unique transcripts and were then connected with the HUGO Gene IDs. A total of 1,175 genes were located \<150 kb from the GWAS SNPs. PANTHER database ([@B22]) (<http://www.pantherdb.org>) was used to identify the underlying biological pathways, and STRING, version 10.5 (<https://string-db.org>), was used to study protein interactions.

For the nearest genes of the top variants, gene expression (Expression Atlas \[<http://www.ebi.ac.uk/gxa/home>\]) and protein expression (ProteomicsDB \[<https://www.proteomicsdb.org>\]) were studied. The ENCODE data wereaccessed through UCSC Genome Browser (<http://www.genome.ucsc.edu>) and RegulomeDB v1.1 (23) (<http://regulome.stanford.edu/> \[July 2017\]). Expression quantitative trait loci (eQTL) of the top variants were studied using the Genotype-Tissue Expression project portal (GTEx V7) (<https://www.gtexportal.org/home/>). PhenoScanner V2 database ([@B24]) (<http://www.phenoscanner.medschl.cam.ac.uk/phenoscanner>) was used to find associations with metabolites.

Results {#s17}
=======

Mean ± SD HbA~1c~ was 8.5 ± 1.2% (69.5 ± 13.1 mmol/mol) in FinnDiane ([Table 1](#T1){ref-type="table"}). Narrow-sense heritability of HbA~1c~ was 17.0% (*P* = 0.002) (unadjusted) or 15.3% (*P* = 0.003) when adjusted for covariates. Minor alleles of three SNPs on chromosome 13q12.3 showed genome-wide significant association with higher HbA~1c~ values in the GWAS (lead SNP rs2085277: β = 0.42 \[95% CI 0.27, 0.56\], *P* = 1.52 × 10^−8^) ([Fig. 2](#F2){ref-type="fig"}). The three SNPs rs2085277, rs1360072, and rs17076364 are in high linkage disequilibrium (LD) in the 1000 Genomes EUR population and are located between β 3-glucosyltransferase (*B3GLCT*) (SNPs 232--261 kb downstream) and 146--175 kb upstream of the closest gene, relaxin family peptide receptor 2 (*RXFP2*) ([Supplementary Fig. 4](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db18-0573/-/DC1)).

###### 

Baseline demographics of the FinnDiane cohort

  ----------------------------------------------------------------- -------------------------
  *n*                                                               4,622
  Sex (% male)                                                      51.0
  Age (years)                                                       38.8 ± 12.4
  HbA~1c~, % (mmol/mol)                                             8.5 ± 1.2 (69.5 ± 13.1)
  Age at diabetes diagnosis (years)                                 13.9 (8.9--21.6)
  Duration of diabetes (years)                                      21.9 (12.4--31.0)
  Number of HbA~1c~ measurements                                    19 (9--32)
  HbA~1c~ collection time (years)[\*](#t1n1){ref-type="table-fn"}   25.4 (22.4--25.4)
  HbA~1c~ measurements (*n*/year)                                   0.9 (0.4--1.4)
  HbA~1c~ variability, CV (%)                                       8.9 (6.8--11.9)
  BMI (kg/m^2^)                                                     25.1 ± 3.7
  Insulin (IU)                                                      50.7 ± 21.3
  Insulin dose (IU/kg)                                              0.70 ± 0.26
  SBP (mmHg)                                                        134 ± 19
  DBP (mmHg)                                                        79 ± 10
  Triglycerides (mmol/L)                                            1.02 (0.76--1.45)
  DN status, *n* (%)                                                
   Normal AER                                                       2,794 (60.5)
   Microalbuminuria                                                 610 (13.2)
   Macroalbuminuria                                                 746 (16.1)
   ESRD                                                             227 (4.9)
   Undefined                                                        245 (5.3)
  Retinopathy, *n* (%)[†](#t1n2){ref-type="table-fn"}               1,530 (34.6)
  Hard event, *n* (%)                                               447 (9.8)
  ----------------------------------------------------------------- -------------------------

Data are mean ± SD or median (interquartile range) unless otherwise indicated. Coefficient of variation (CV) is defined as CV = SD/mean ×100 and calculated from T1D subjects with three or more HbA~1c~ measurements. Cardiovascular hard events were myocardial infarction, cardiac bypass surgery, stroke, peripheral vascular disease, or amputation at baseline. HbA~1c~ measurements between 1991 or 1 year after diabetes diagnosis year and 1 June 2016 or before the ESRD year were collected. DBP, diastolic blood pressure; SBP, systolic blood pressure.

\*HbA~1c~ collection time is calculated as years between the beginning of the HbA~1c~ collection (1 January 1991 or 1 year after diabetes diagnosis year) and the end of the collection (1 June 2016 or ESRD year).

†Laser-treated diabetic retinopathy.

![Manhattan plot of the FinnDiane HbA~1c~ GWAS results shows genome-wide significant (*P* \< 5.0 ×10^−8^) variants on chromosome 13. The lead SNP is rs2085277 (*P* = 1.52 ×10^−8^). *y*-axis shows the --log~10~ *P* value, and *x*-axis tells the chromosomal position of the variants. The two horizontal lines denote the thresholds for genome-wide significant *P* value of 5 × 10^−8^ (upper dashed line) and for a suggestive association with *P* value of 5 ×10^−6^ (lower dotted line).](db180573f2){#F2}

Additional genotyping confirmed the imputed rs2085277 and rs17076364 genotypes ([Supplementary Table 3](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db18-0573/-/DC1)). The lead SNP rs2085277 was not significantly associated with insulin dose (IU/kg), coefficient of variation of HbA~1c~ ([Supplementary Table 4](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db18-0573/-/DC1)), or hematocrit or other hematological parameters that were measured in a small subcohort of 429 individuals with T1D ([Supplementary Table 5](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db18-0573/-/DC1)). Altogether, 68 variants had *P* \< 5 × 10^−6^ in the GWAS. Of these, five tightly correlated SNPs from chr13 locus and eight other independent SNPs with *P* \< 5 × 10^−6^ were selected for replication and subsequent analyses. Notably, these variants were associated with HbA~1c~ also when longitudinal HbA~1c~ measurements were analyzed in a subcohort of 4,153 individuals with three or more HbA~1c~ measurements ([Supplementary Table 6](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db18-0573/-/DC1)).

Replication {#s18}
-----------

### T1D Cohorts {#s19}

The five T1D cohorts all used the mean of the natural log-transformed HbA~1c~ values as the end phenotype. Two SNPs showed significant replication with ln(HbA~1c~): rs373883321 in CACTI~clinic~ (chr6:165,403,975, *P* = 0.006) and rs10459356 near the lead SNP rs2085277 on chromosome 13 in RASS (*P* = 0.042) ([Supplementary Table 7](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db18-0573/-/DC1)). In a meta-analysis with the discovery cohort, variants rs2085277 and rs1360072 in high LD on chromosome 13 were significantly associated with ln(HbA~1c~) with β = 0.046 (95% CI 0.030, 0.063) and *P* = 3.7 × 10^−8^ and *P* = 4.2 × 10^−8^, respectively ([Table 2](#T2){ref-type="table"} and [Supplementary Table 8](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db18-0573/-/DC1)).

###### 

Top loci in the FinnDiane HbA~1c~ GWAS and results from replication in other T1D cohorts

  Variant       Position        Closest gene   FinnDiane (*n* = 4,622)   T1D replication cohorts   Meta-analysis *P*                                    
  ------------- --------------- -------------- ------------------------- ------------------------- ------------------- -------------- ---------- ------ --------------
  rs7514675     1:99,782,478    *LPPR4*        G/A                       10.1                      0.23 (0.13, 0.33)   2.7 × 10^−6^   7; 3,097   12.4   1.5 × 10^−2^
  rs144918527   3:12,740,810    *RAF1*         T/TTG                     53.2                      0.13 (0.08, 0.19)   4.4 × 10^−6^   5; 2,248   51.2   2.5 × 10^−4^
  rs373883321   6:165,403,975   *MEAT6*        T/--                      34.4                      0.13 (0.07, 0.18)   3.9 × 10^−6^   5; 2,248   36.8   2.1 × 10^−2^
  rs478414      7:154,526,318   *DPP6*         C/T                       56.0                      0.13 (0.07, 0.18)   3.1 × 10^−6^   7; 3,097   50.5   8.3 × 10^−3^
  rs113241624   8:109,658,463   *TMEM74*       A/G                       1.2                       0.60 (0.35, 0.85)   3.2 × 10^−6^   1; 596     1.0    8.5 × 10^−5^
  rs4744017     9:93,615,717    *SYK*          A/G                       47.9                      0.12 (0.07, 0.17)   8.8 × 10^−6^   7; 3,097   46.8   8.3 × 10^−4^
  rs2085277     13:32,167,717   *RXFP2*        T/A                       4.1                       0.42 (0.27, 0.56)   1.5 × 10^−8^   1; 253     1.0    3.7 × 10^−8^
  rs552894079   15:89,840,012   *FANCI*        A/G                       97.6                      0.40 (0.23, 0.56)   8.1 × 10^−6^   NA         NA     NA
  rs2599441     19:43,989,088   *PHLDB3*       G/A                       72.8                      0.14 (0.08, 0.19)   2.0 × 10^−6^   7; 3,097   76.2   3.2 × 10^−3^

EA, effect allele; EAF, effect allele frequency; OA, other allele.

\*β is the effect size for the mean HbA~1c~ phenotype in the discovery cohort. Replication cohorts are two DCCT/EDIC cohorts (conventional \[*n* = 667\] and intensive \[*n* = 637\] treatment of HbA~1c~ in the DCCT separately), WESDR (*n* = 596), RASS (*n* = 253), CACTI divided into two cohorts (nonclinic \[*n* = 253\] and clinic \[*n* = 265\]), and EDC (*n* = 253). Since the mean of natural log-transformed HbA~1c~ was the phenotype used in the T1D replication cohorts, top SNP association with ln(HbA~1c~) was further calculated in the discovery cohort to get comparable βs and SEs for the meta-analysis. Meta-analysis *P* value is from fixed-effects meta-analysis of FinnDiane and all replication cohorts restricted to variants with MAF ≥1% in the individual replication cohorts. Results for the variants rs1360072 and rs17076364 on chromosome 13 locus were similar to the top variant, rs2085277: FinnDiane, *P* = 1.8 × 10^−8^ and *P* = 2.6 × 10^−8^, and meta-analysis, *P* = 4.2 × 10^−8^ and *P* = 6.5 × 10^−8^, respectively. rs113241624 on chromosome 8 had MAF ≥1% only in WESDR and rs2085277 on chromosome 13 only in RASS. SNP rs552894079 was not available in the T1D replication cohorts.

Of note, the MAFs for rs2085277 and rs1360072 on chromosome 13 were 4% in FinnDiane and 1% in RASS but only 0.2%--0.5% in the DCCT/EDIC and WESDR cohorts that were thus not included in the meta-analysis for these SNPs ([Supplementary Fig. 5](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db18-0573/-/DC1)). Because of low imputation quality of the chr13 top variants (*r*^2^ \< 0.60), CACTI and EDC cohorts were also excluded from the meta-analysis of these SNPs. Low MAFs reduced the statistical power to replicate the findings, but in RASS the effect was in the same direction as in FinnDiane: lead SNP rs2085277, β = 0.059 \[95% CI --0.079, 0.198\] for ln(HbA~1c~), *P* = 0.402. The MAF for rs2085277 is similar to our study in the 1000 Genomes populations: 5.6% in FIN (Finnish in Finland), 0.5% in GBR (British in England and Scotland), and 0% (monomorphic) in the CEU (Northern Europeans from Utah). The variant showed a markedly higher frequency in East Asians and South Asians with MAFs of 38.5% and 9.2%, respectively.

### Cohorts Without Diabetes {#s20}

The association of the thirteen SNPs with HbA~1c~ was then queried in GWAS meta-analysis data on multiple cohorts without diabetes. As expected due to low MAF in Europeans, no data were available for the chr13 top SNPs or for any proxy SNPs with *r*^2^ ≥ 0.3 in the European cohorts. Therefore, replication of the chr13 variants was sought in the meta-analysis results of individuals of Asian ancestry. The SNPs were missing from the South Asian cohorts, but the chr13 top SNPs rs2085277 and rs1360072 were associated with HbA~1c~ (%) in East Asians with β = 0.02 (95% CI 0.006, 0.03), *P* = 0.005, and β = 0.02 (0.003, 0.03), *P* = 0.013, respectively. ([Table 3](#T3){ref-type="table"}). None of the other top SNPs or the proxy variants were associated with HbA~1c~ in the Europeans ([Supplementary Table 9](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db18-0573/-/DC1)).

###### 

Three genome-wide significant variants on chromosome 13: LD structures and HbA~1c~ association in a population without diabetes

  Variant      EA \< OA   MAF (%)[\*](#t3n1){ref-type="table-fn"}   *r*^2^[†](#t3n2){ref-type="table-fn"}   HbA~1c~ association in a Finnish T1D cohort   HbA~1c~ association in an East Asian population without diabetes                                                                                       
  ------------ ---------- ----------------------------------------- --------------------------------------- --------------------------------------------- ------------------------------------------------------------------ ------- ------ ------ ----- ------------------- -------------- -------------------- -------
  rs2085277    T \< A     4.2                                       38.5                                    9.2                                           1.2                                                                                            0.42 (0.27, 0.56)   1.5 × 10^−8^   0.02 (0.006, 0.03)   0.005
  rs1360072    C \< T     4.1                                       34.6                                    9.0                                           1.2                                                                1.0     0.75   0.95   1.0   0.41 (0.27, 0.56)   1.8 × 10^−8^   0.02 (0.003, 0.03)   0.013
  rs17076364   T \< C     3.1                                       2.5                                     0.2                                           1.2                                                                0.97    0.04   0.02   1.0   0.45 (0.29, 0.61)   2.6 × 10^−8^   NA                   NA
  *n*                     4,622                                     504                                     503                                           489                                                                4,622   504    503    489   4,622                              23,461               

EA is the effect allele in the FinnDiane GWAS and OA is the other allele.

\*MAF frequency in the FinnDiane cohort (FD) and in East Asian (EAS), South Asian (SAS), and EUR populations in the 1000 Genomes phase 3 data.

†LD (*r*^2^) with rs2085277 in the FinnDiane and in the 1000 Genomes phase 3 populations. Position of the SNPs in the human genome build GRCh37 (hg19) was rs2085277, chr13:32,167,717; rs1360072, chr13:32,138,331; and rs17076364: chr13:32,163,399. HbA~1c~ association statistics for these variants were not available for the European population without diabetes (*n* = 123,517) or South Asian population without diabetes (*n* = 9,908) (Wheeler et al. \[[@B6]\]).

In Silico Analyses {#s21}
------------------

Interestingly, minor T allele for rs2085277 was associated with higher levels of ketone bodies acetoacetate and 3-hydroxybutyrate ([@B25]) (PhenoScanner) (*P* = 0.003 and *P* = 0.020, respectively). No direct ENCODE data were available for rs2085277, and only minimal transcription factor--binding evidence (RegulomeDB scores 4--6) was seen for other top SNPs in the chr13 locus. Although none of the chr13 top variants were included in the GTEx database, many SNPs near rs2085277 affect the expression of *RXFP2* in adrenal gland, which suggests that rs2085277 might also affect *RXFP2* expression.

*RXFP2* belongs to the positive regulation of cAMP biosynthetic process pathway (Gene Ontology term in the STRING protein network analysis \[[Fig. 3](#F3){ref-type="fig"}\]). Interestingly, when the search was restricted to databases as opposed to all interaction sources (databases, text mining, experiments, coexpression, neighborhood, gene fusion, and co-occurrence), gastric inhibitory polypeptide receptor (GIPR) and glucagon (GCG)---proteins relevant for glucose homeostasis and diabetes---occurred in the same protein interaction network with RXFP2.

![Protein networks around RXFP2 (red). *A*: Two most enriched Gene Ontology (GO) biological pathways were "cellular response to glucagon stimulus" (GNB1, GNB4, GNB2, and GNB3) and "positive regulation of cAMP biosynthetic process" (RXFP2, RLN2 \[relaxin\], AVPR2, and INSL3), with false discovery rates 4.6 ×10^−5^ and 2.8 ×10^−4^, respectively. Protein network was generated with STRING, version 10.5, selecting all active interaction sources, minimum required interaction score 0.90 (highest confidence), and no more than 10 interactions. *B*: Only database interaction sources were selected with minimum required interaction score 0.90 (highest confidence) and no more than 10 interactions. Six out of 11 proteins in this network belong to "positive regulation of cAMP biosynthetic process" (GO biological process), which was the most enriched pathway in this network, connecting proteins RXFP2, GIPR, GCG, ADCYAP1, MC1R, and FSHR (false discovery rate 1.3 ×10^−8^). Of note is that gastric inhibitory polypeptide receptor (GIPR) and glucagon (GCG) present in this protein network have a high relevance in glucose homeostasis and diabetes.](db180573f3){#F3}

Genes involved in cell-cell adhesion processes and developmental processes were overrepresented in GWAS results (PANTHER, *P* \< 0.05, corrected for multiple testing \[[Supplementary Table 10](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db18-0573/-/DC1)\]). PANTHER pathway analysis pointed out cadhenin signaling, endogenous cannabinoid signaling, and Wnt signaling pathways (*P* \< 0.05, corrected for 160 independent classes).

Duration of Diabetes and Chronic Diabetes Complications {#s22}
-------------------------------------------------------

Our GWAS top variants had a consistent effect on HbA~1c~ irrespective of diabetes duration. In all 10-year diabetes duration bins, the GRS~FD~ ([Supplementary Table 11](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db18-0573/-/DC1) and [Supplementary Fig. 6](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db18-0573/-/DC1)) was significantly associated with HbA~1c~ ([Supplementary Table 12](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db18-0573/-/DC1)). We confirmed this constant association between GRS~FD~ and HbA~1c~ in a small group of individuals (*n* = 271) having HbA~1c~ measurements from three consecutive diabetes duration bins: 1--9.9, 10--19.9, and 20--29.9 years.

Subjects with T1D with DN had higher mean HbA~1c~ compared with individuals with normal AER (8.9 ± 1.3% vs. 8.2 ± 1.0%, *P* \< 10^−16^). Similarly, individuals with diabetic retinopathy had higher HbA~1c~ compared with non--laser-treated subjects with at least 15 years of diabetes duration (8.8 ± 1.2% vs. 8.4 ± 1.2%, *P* \< 10^−16^). As expected, individuals with DN had higher GRS~FD~ (6.5 vs. 6.4, *P* = 0.038), while the subjects with diabetic retinopathy did not have higher GRS~FD~ (*P* = 0.205).

Previous HbA~1c~ Studies {#s23}
------------------------

rs1358030 was previously associated with HbA~1c~ in the GWAS of 1,307 individuals with T1D ([@B10]). However, this association was not replicated in FinnDiane, although the MAFs were similar (MAF~DCCT~ = 36% vs. MAF~FinnDiane~ = 40%), imputation quality was *r*^2^ = 0.99, and the effect was in the same direction (β = 0.034 \[95% CI --0.02, 0.09\], *P* = 0.192) ([Supplementary Table 13](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db18-0573/-/DC1)).

Of the SNPs identified in populations without diabetes, four variants were associated with HbA~1c~ in FinnDiane: the minor A allele of the missense variant rs1800562 in *HFE* was associated with lower HbA~1c~ (*P* = 0.007) with higher effects size than in the population without diabetes ([Fig. 4](#F4){ref-type="fig"}). The HbA~1c~ values for the genotypes AA (*n* = 3), AG (*n* = 250), and GG (*n* = 4,369) were 7.6 ± 1.1%, 8.3 ± 1.2%, and 8.5 ± 1.2%, respectively. Variants rs906216 and rs7072268 in *HK1* and rs12621844 near *FOXN2* were also directionally consistently associated with HbA~1c~ in FinnDiane (*P* \< 0.05) ([Supplementary Tables 13 and 14](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db18-0573/-/DC1)). Of note, 16 of 19 SNPs classified as erythrocytic variants by Wheeler et al. ([@B6]) showed similar direction of effect in FinnDiane compared with the original study (binomial test for enrichment, *P* = 0.002 \[[Fig. 4](#F4){ref-type="fig"}\]).

![Effect sizes (βs) of 55 variants associated with HbA~1c~ (%) in the original study by Wheeler et al. ([@B6]) (European population without diabetes on *x*-axis) and in FinnDiane (T1D cohort on *y*-axis). The SNPs were classified into three groups (erythrocytic SNPs, glycemic SNPs, or unclassified SNPs) in the study by Wheeler et al. based on the literature search of known associations of the SNPs in earlier published GWAS for glycemic or erythrocytic traits. Horizontal dashed line denotes the effect size zero (β = 0) in FinnDiane indicating that variants with β \> 0 have the effect on HbA~1c~ in the same direction as in the population without diabetes. SNPs above the diagonal dotted line have a stronger effect on HbA~1c~ in the T1D cohort. Two SNPs with HbA~1c~ association *P* \< 0.05 in FinnDiane are indicated by arrows. Gene names are shown for these variants and for *HK1* because this particular SNP (rs4745982) in *HK1* was not associated with HbA~1c~ in FinnDiane. Instead, two other SNPs in *HK1* (rs906216 and rs7072268 from Paré et al. \[[@B1]\]) showed significant association with HbA~1c~ in FinnDiane. *FOXN2*, forkhead box protein N2; *HFE*, hemochromatosis; *HK1*, hexokinase.](db180573f4){#F4}

### GRS {#s24}

Next, we tested the combined genetic effect by creating GRS from significant variants found in the largest HbA~1c~ GWAS ([@B6]) ([Supplementary Fig. 7](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db18-0573/-/DC1)). A GRS-ALL comprising 55 SNPs was associated with HbA~1c~ in FinnDiane (β = 0.010 \[95% CI 0.002, 0.018\], *P* = 0.014) and, along with covariates, explained 2.5% of the variation in HbA~1c~. However, age, diabetes duration, sex, and *n*HbA~1c~ alone explained 2.4% of the variation, whereas GRS-ALL explained only 0.1% of the variation in HbA~1c~. A similar amount of HbA~1c~ variance was also explained by GRS-E including only 19 erythrocytic SNPs (β = 0.021 \[95% CI 0.005, 0.037\], *P* = 0.01). In contrast, GRS-G created from the 18 glycemic variants was not associated with HbA~1c~ (β = 0.004 \[95% CI --0.01, 0.018\], *P* = 0.573).

Discussion {#s25}
==========

We identified a locus on chromosome 13 that show genome-wide significant association with HbA~1c~ in 4,622 Finnish individuals with T1D. The three associated SNPs in the locus are located \<30 kb from each other and are in high LD, therefore indicating the same association signal. Notably, the association with HbA~1c~ at rs2085277 and rs1360072 remained genome-wide significant in a meta-analysis including individuals with T1D from RASS. In DCCT/EDIC and WESDR, the MAFs for the chr13 top SNPs were ≤0.5%. The low MAFs (≤1%) might explain the lack of significant replication in the T1D cohorts, since the power to detect significant association with MAF ≤1% is limited. On the contrary, both SNP associations were replicated (*P* ≤ 0.013) in the East Asian population without diabetes, where the SNPs were present with high allelic frequency of 38.5% and 34.5% for rs2085277 and rs1360072, respectively.

rs2085277 is an intergenic SNP surrounded by *B3GLCT* (261 kb 5′) and *RXFP2* (146 kb 3′). More distant *B3GLCT* is a glucosyltransferase that adds glucose molecules to multiple proteins. *RXFP2* seems a more plausible candidate gene, since many SNPs in close vicinity to rs2085277 (although not in LD) have *cis*-eQTLs for *RXFP2* in adrenal gland. RXFP2 is a receptor for insulin-like peptide 3 (INSL3) and relaxin, and RXFP2 is expressed at low levels in many tissues. ProteomicsDB shows RXFP2 expression in adrenal glands and in pancreatic islets. Although the pharmacology and biology of relaxin receptors are relatively well-known ([@B26]), we are not aware of any previous studies on RXFP2 in relation to glucose homeostasis. Of note, protein interaction analysis restricted to databases shows that RXFP2 is linked to the glucagon response pathway and to relevant proteins for glucose homeostasis, like GIPR and GCG. Interestingly, adenylate cyclase 5 (ADCY5), which has previously been linked to HbA~1c~ and T2D ([@B6],[@B27]), is found in the same protein interaction network. However, there is yet no experimental evidence that would link these proteins. Thus, the biological mechanisms by which RXFP2 possibly affects HbA~1c~ remain to be elucidated.

RXFP2 stimulates adenylate cyclase to increase intracellular second messenger cAMP concentrations. The main ligand for RXFP2 is relaxin hormone, which is naturally increased in pregnancy, and it has both vasodilative and antifibrotic actions ([@B26]). Interestingly, relaxin might act along with insulin to control blood glucose homeostasis ([@B28]). This was also suggested by a study in mice, where relaxin treatment ameliorated the insulin sensitivity of mice on a high-fat diet ([@B29]). The main receptor for human relaxin is relaxin family peptide receptor 1 (RXFP1) but, to a smaller extent, relaxin is also a ligand for RXFP2.

Our main phenotype was mean HbA~1c~, which was based on a median of 19 measurements per individual. One limitation of the study is that some individuals had only one HbA~1c~ measurement. A single HbA~1c~ measurement is not optimal for T1D studies, since HbA~1c~ values tend to vary within a person over time. When a smaller subcohort of FinnDiane patients with three or more HbA~1c~ measurements was studied with another method, linear mixed models, all top variants were consistently associated with HbA~1c~, although the effect sizes tended to be smaller. This was maybe due to a smaller cohort (*n* = 4,153) and deviation from the linear trend over time (individual slopes) in the HbA~1c~ values.

In diabetes, HbA~1c~ values are used as an indicator of glycemic control achieved with insulin treatment or with drugs improving insulin sensitivity, the latter mainly used in patients with type 2 diabetes. The heritability estimate for HbA~1c~ in our study was modest but significant (*h*^2^ = 15%) and confirmed that HbA~1c~ in T1D can hold a heritable component ([@B30]). In the HbA~1c~ GWAS in DCCT, a variant near *SORCS1* was found. We were, however, unable to replicate the finding, although the effect was in the same direction. The lack of replication may be due to the winner's curse, which causes the effect in the discovery cohort to be overestimated, and therefore the power for replicating the true smaller genetic effect is lower. Here, we had 100% power to replicate rs1358030 with a β = 0.045 \[for ln(HbA~1c~)\] and only 62% power with a β = 0.003 corrected for winner's curse with a bootstrap method at two-sided α = 0.05 ([@B31]). On the other hand, four variants in or near *HFE*, *HK1*, and *FOXN2* originally found in cohorts without diabetes were also associated with HbA~1c~ (*P* \< 0.05) in FinnDiane.

Variants associated with HbA~1c~ have mostly been discovered in large GWAS meta-analyses and have relatively small effect sizes. Therefore, the power to replicate these variants in our study was only ≤33%. However, a GRS comprising 55 SNPs associated with HbA~1c~ in our T1D cohort, although it explained only a small part of the variation of HbA~1c~. Interestingly, when divided into erythrocytic and glycemic risk scores, GRS-E including only 19 variants classified as erythrocytic SNPs was also associated with HbA~1c~, while no association was seen for the glycemic risk score. This is expected, as the erythrocyte biology can be expected to be similar in individuals with and without diabetes, but the mechanisms affecting the level of glycemia are presumably different in individuals with T1D compared with the individuals without diabetes. As discussed by Wheeler et al. ([@B6]), the genetic factors primarily affecting erythrocyte biology may result in falsely high or low HbA~1c~ levels no longer fully reflecting the level of glycemia and, thus, in false interpretation of HbA~1c~.

Allele frequencies of risk variants may differ between populations, and therefore it is important to conduct genetic analyses in different populations. Finns represent a population that has been genetically isolated from the rest of Europe, thus presenting an interesting opportunity to explore genetic variants affecting HbA~1c~ in T1D. Indeed, the lead SNP was observed with a markedly higher MAF in the Finnish than in non-Finnish Europeans.

To conclude, we identified a locus on chromosome 13 near *RXFP2* that is associated with HbA~1c~ in individuals with T1D. Further studies are needed to find out whether relaxin hormone mediates the effect of *RXFP2* on HbA~1c~. Since effect sizes are expected to be smaller in the population without diabetes, additional replication of the top locus as well as the search for additional genetic factors affecting HbA~1c~ in other T1D cohorts is warranted. As HbA~1c~ has a major influence on the development of diabetes complications, it is important to continue the search for genetic variants affecting HbA~1c~.
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======================

###### Supplementary Data

This article contains Supplementary Data online at <http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db18-0573/-/DC1>.

A complete list of the DCCT/EDIC Research Group and the FinnDiane Study Group can be found in the Supplementary Data online.
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